[{"id":"1bc7d467-7896-491d-8c0c-8c4bb935a5f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03972657","created_at":"2023-08-08T17:08:39.649Z","updated_at":"2024-07-02T16:35:15.522Z","phase":"Phase 1/2","brief_title":"A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors","source_id_and_acronym":"NCT03972657","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab) • nezastomig (REGN5678)"],"overall_status":"Recruiting","enrollment":" Enrollment 345","initiation":"Initiation: 08/12/2019","start_date":" 08/12/2019","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 07/03/2026","study_completion_date":" 07/03/2026","last_update_posted":"2024-03-08"}]